CN114569566A - 一种盐酸米那普仑制剂的制备方法 - Google Patents
一种盐酸米那普仑制剂的制备方法 Download PDFInfo
- Publication number
- CN114569566A CN114569566A CN202011394242.5A CN202011394242A CN114569566A CN 114569566 A CN114569566 A CN 114569566A CN 202011394242 A CN202011394242 A CN 202011394242A CN 114569566 A CN114569566 A CN 114569566A
- Authority
- CN
- China
- Prior art keywords
- parts
- milnacipran hydrochloride
- preparation
- adhesive
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XNCDYJFPRPDERF-PBCQUBLHSA-N Milnacipran hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1C[NH3+] XNCDYJFPRPDERF-PBCQUBLHSA-N 0.000 title claims abstract description 113
- 229960000638 milnacipran hydrochloride Drugs 0.000 title claims abstract description 113
- 238000002360 preparation method Methods 0.000 title claims abstract description 106
- 239000000843 powder Substances 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 89
- 238000002156 mixing Methods 0.000 claims abstract description 75
- 239000003814 drug Substances 0.000 claims abstract description 66
- 239000002994 raw material Substances 0.000 claims abstract description 49
- 238000007873 sieving Methods 0.000 claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 claims abstract description 41
- 238000000576 coating method Methods 0.000 claims abstract description 40
- 239000000853 adhesive Substances 0.000 claims abstract description 34
- 230000001070 adhesive effect Effects 0.000 claims abstract description 34
- 239000011248 coating agent Substances 0.000 claims abstract description 34
- 239000000945 filler Substances 0.000 claims abstract description 31
- 239000011162 core material Substances 0.000 claims abstract description 27
- 239000000314 lubricant Substances 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 239000007884 disintegrant Substances 0.000 claims abstract description 12
- 238000000465 moulding Methods 0.000 claims abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 70
- 230000008569 process Effects 0.000 claims description 63
- 235000019359 magnesium stearate Nutrition 0.000 claims description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 23
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 22
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 17
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 16
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 16
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 15
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- 239000007888 film coating Substances 0.000 claims description 6
- 238000009501 film coating Methods 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 229960003943 hypromellose Drugs 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 229910002012 Aerosil® Inorganic materials 0.000 claims 1
- ARLZGEXVMUDUQZ-UHFFFAOYSA-N O.O.[Ca] Chemical compound O.O.[Ca] ARLZGEXVMUDUQZ-UHFFFAOYSA-N 0.000 claims 1
- 230000007547 defect Effects 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 37
- 229940079593 drug Drugs 0.000 description 31
- 239000000463 material Substances 0.000 description 21
- 238000005303 weighing Methods 0.000 description 20
- 239000012535 impurity Substances 0.000 description 15
- 238000005070 sampling Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 238000004513 sizing Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000005550 wet granulation Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 239000011812 mixed powder Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000000227 grinding Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- 238000005265 energy consumption Methods 0.000 description 5
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- 238000009702 powder compression Methods 0.000 description 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 229960000600 milnacipran Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- XNCDYJFPRPDERF-UHFFFAOYSA-N 2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropane-1-carboxamide;hydron;chloride Chemical compound Cl.C=1C=CC=CC=1C1(C(=O)N(CC)CC)CC1CN XNCDYJFPRPDERF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000685 levomilnacipran Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000009725 powder blending Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 229910021487 silica fume Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Abstract
Description
样品 | 预混 | 总混 |
1 | 98.8 | 99.5 |
2 | 98.6 | 96.2 |
3 | 97.3 | 98.6 |
4 | 99.8 | 100.1 |
5 | 98.7 | 99.6 |
6 | 97.5 | 97.9 |
7 | 99.5 | 99.3 |
8 | 98.8 | 97.2 |
9 | 98.4 | 97.5 |
10 | 96.7 | 98.7 |
平均% | 98.4 | 98.5 |
RSD% | 1.0 | 1.2 |
样品 | 预混 | 总混 |
1 | 98.9 | 96.9 |
2 | 96.6 | 96.3 |
3 | 100.2 | 98.5 |
4 | 100.1 | 99.1 |
5 | 98.7 | 97.9 |
6 | 97.8 | 98.0 |
7 | 98.8 | 97.4 |
8 | 100.0 | 98.5 |
9 | 97.8 | 98.0 |
10 | 101.5 | 100.2 |
平均% | 99.0 | 98.1 |
RSD% | 1.4 | 1.1 |
样品 | 预混 | 总混 |
1 | 103.2 | 98.8 |
2 | 104.9 | 95.2 |
3 | 97.0 | 100.5 |
4 | 96.4 | 97.7 |
5 | 99.0 | 102.8 |
6 | 102.9 | 97.7 |
7 | 96.4 | 101.1 |
8 | 96.2 | 107.6 |
9 | 96.7 | 110.4 |
10 | 116.8 | 100.6 |
平均% | 101.0 | 101.2 |
RSD% | 6.5 | 4.7 |
样品 | 混①30min | 混②50min | 混③60min |
1 | 112.2 | 110.2 | 96 |
2 | 108.9 | 109.9 | 95.6 |
3 | 96 | 98 | 102.5 |
4 | 95.5 | 96.4 | 96.3 |
5 | 113.7 | 96 | 100.8 |
6 | 106.2 | 102.9 | 95.7 |
7 | 96.3 | 96.4 | 98.1 |
8 | 95 | 95.2 | 108.6 |
9 | 97.4 | 97.7 | 110 |
10 | 98.2 | 107.8 | 109.6 |
平均% | 101.9 | 101.05 | 101.32 |
RSD% | 7.5 | 6.1 | 6.0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011394242.5A CN114569566A (zh) | 2020-12-02 | 2020-12-02 | 一种盐酸米那普仑制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011394242.5A CN114569566A (zh) | 2020-12-02 | 2020-12-02 | 一种盐酸米那普仑制剂的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114569566A true CN114569566A (zh) | 2022-06-03 |
Family
ID=81768412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011394242.5A Pending CN114569566A (zh) | 2020-12-02 | 2020-12-02 | 一种盐酸米那普仑制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114569566A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232387A (zh) * | 1996-08-28 | 1999-10-20 | 皮埃尔法博赫药品公司 | 延长释放米那普仑的盖伦制剂 |
WO1999061027A1 (en) * | 1998-05-22 | 1999-12-02 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
WO2005121151A2 (en) * | 2004-05-17 | 2005-12-22 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
CN105640908A (zh) * | 2014-11-22 | 2016-06-08 | 哈尔滨圣吉药业股份有限公司 | 一种盐酸米那普仑缓释片及其制备方法 |
CN111671731A (zh) * | 2020-07-30 | 2020-09-18 | 上海现代制药股份有限公司 | 一种含有盐酸米那普仑的速释制剂及其制备方法 |
-
2020
- 2020-12-02 CN CN202011394242.5A patent/CN114569566A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232387A (zh) * | 1996-08-28 | 1999-10-20 | 皮埃尔法博赫药品公司 | 延长释放米那普仑的盖伦制剂 |
WO1999061027A1 (en) * | 1998-05-22 | 1999-12-02 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
WO2005121151A2 (en) * | 2004-05-17 | 2005-12-22 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
CN105640908A (zh) * | 2014-11-22 | 2016-06-08 | 哈尔滨圣吉药业股份有限公司 | 一种盐酸米那普仑缓释片及其制备方法 |
CN111671731A (zh) * | 2020-07-30 | 2020-09-18 | 上海现代制药股份有限公司 | 一种含有盐酸米那普仑的速释制剂及其制备方法 |
Non-Patent Citations (1)
Title |
---|
PUNIT B. PAREJIYA ET AL: "Development of Platform Technology for Oral Controlled Delivery of Highly Water Soluble Drugs Using Milnacipran HCl as a Model Drug" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105213346B (zh) | 一种含有盐酸西那卡塞的药物组合物及其制备方法 | |
CN110420192B (zh) | 一种单硝酸异山梨酯缓释片及制备方法 | |
CN106265581B (zh) | 一种氨甲环酸片及其制备方法 | |
CN108567759A (zh) | 一种缬沙坦氢氯噻嗪片及其制备方法 | |
CN114569566A (zh) | 一种盐酸米那普仑制剂的制备方法 | |
CN108498470A (zh) | 一种氟哌噻吨美利曲辛药物组合物及其制备方法 | |
CN102764254A (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
CN102755300A (zh) | 一种伏立康唑组合物及其制备方法 | |
CN104666263B (zh) | 一种含有左乙拉西坦的片剂及其制备方法 | |
WO2022062096A1 (zh) | 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物 | |
CN114748435A (zh) | 一种盐酸多奈哌齐口崩片及其制备方法 | |
CN111000812B (zh) | 一种拉考沙胺片的制备方法 | |
CN108743554A (zh) | 一种甲苯磺酸依度沙班片剂及其制备方法 | |
CN113018270A (zh) | 一种高稳定的盐酸米那普仑制剂及其制备方法 | |
CN103181905A (zh) | 一种制备盐酸普拉克索片剂的工艺 | |
CN112826806A (zh) | 一种缬沙坦片制备方法和缬沙坦片 | |
CN110025588A (zh) | 缬沙坦氨氯地平片的制备方法及其加工系统 | |
CN115350178B (zh) | 一种包含左乙拉西坦的药物组合物 | |
CN111184695A (zh) | 琥珀酸普芦卡必利的片剂组合物及其制备方法 | |
CN103463082A (zh) | 一种替米沙坦氨氯地平双层片及其制备方法 | |
CN111358795A (zh) | 一种枸橼酸托法替布制剂及其制备方法 | |
CN117045610B (zh) | 一种溶出高稳定性的盐酸拉贝洛尔组合物及其制备方法 | |
CN113855640B (zh) | 治疗精神疾病的固体药物组合物 | |
CN111228229A (zh) | 一种盐酸索他洛尔片剂及其制备工艺 | |
CN109966262A (zh) | 来那度胺药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 646000 Luzhou national high tech Zone pharmaceutical industrial park, Luxian County, Luzhou City, Sichuan Province Applicant after: SICHUAN CREDIT PHARMACEUTICAL Co.,Ltd. Applicant after: Sichuan Keride Zhongling Food Co.,Ltd. Address before: 646000 Luzhou national high tech Zone pharmaceutical industrial park, Luxian County, Luzhou City, Sichuan Province Applicant before: SICHUAN CREDIT PHARMACEUTICAL Co.,Ltd. Country or region before: China Applicant before: Sichuan Zhongling chuangtuo Pharmaceutical Technology Co.,Ltd. |